8,533 Shares in Exelixis, Inc. $EXEL Acquired by Occidental Asset Management LLC

Key Points

• Occidental Asset Management LLC acquired 8,533 shares of Exelixis, Inc., valued at approximately $376,000, in the second quarter.
• Exelixis recently reported $0.75 EPS for the quarter, exceeding estimates of $0.63, though revenue of $568.26 million was slightly below forecasts.
• Analyst ratings for Exelixis show a consensus of "Moderate Buy", with fourteen "Buy" ratings and a target price around $44.42.

Occidental Asset Management LLC bought a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 8,533 shares of the biotechnology company's stock, valued at approximately $376,000.

A number of other large investors also recently bought and sold shares of the stock. Fuller & Thaler Asset Management Inc. boosted its holdings in shares of Exelixis by 2.2% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company's stock valued at $287,794,000 after purchasing an additional 164,134 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Exelixis by 73.8% in the 1st quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company's stock worth $250,869,000 after buying an additional 2,926,884 shares during the period. Invesco Ltd. raised its position in shares of Exelixis by 40.2% in the 1st quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company's stock worth $205,725,000 after buying an additional 1,596,948 shares during the period. Nuveen LLC acquired a new position in Exelixis in the first quarter valued at $123,310,000. Finally, Charles Schwab Investment Management Inc. grew its position in Exelixis by 2.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 3,321,407 shares of the biotechnology company's stock valued at $122,626,000 after acquiring an additional 69,054 shares during the period. Hedge funds and other institutional investors own 85.27% of the company's stock.

Exelixis Stock Up 0.6%

Shares of NASDAQ EXEL opened at $39.81 on Wednesday. The stock's 50 day moving average price is $39.32 and its two-hundred day moving average price is $39.71. Exelixis, Inc. has a 52-week low of $25.17 and a 52-week high of $49.62. The stock has a market capitalization of $10.72 billion, a P/E ratio of 19.14, a PEG ratio of 0.82 and a beta of 0.32.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.63 by $0.12. The company had revenue of $568.26 million during the quarter, compared to analyst estimates of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The business's revenue was down 10.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. On average, analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Guggenheim restated a "buy" rating and set a $45.00 price target on shares of Exelixis in a research note on Tuesday, July 29th. Zacks Research downgraded shares of Exelixis from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 26th. Royal Bank Of Canada cut their price target on shares of Exelixis from $50.00 to $45.00 and set a "sector perform" rating on the stock in a report on Tuesday, July 29th. Wall Street Zen cut shares of Exelixis from a "buy" rating to a "hold" rating in a research report on Monday, September 15th. Finally, Stifel Nicolaus increased their price objective on shares of Exelixis from $38.00 to $41.00 and gave the stock a "hold" rating in a research report on Tuesday, July 29th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $44.42.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.